Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2016-05-18 Share Issue/Capital Cha…
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Share Issue/Capital Change 2016
Share Issue/Capital Change Classification · 99% confidence The document is explicitly titled "Company Announcement" and details a specific corporate action: an increase in share capital resulting from the exercise of employee warrants. This action directly impacts the company's capital structure and share count. Reviewing the definitions, the category "Share Issue/Capital Change (Code: SHA)" is the most appropriate fit, as it covers announcements regarding new share issues or capital structure changes. It is not an Earnings Release (ER), Interim Report (IR), or a general Regulatory Filing (RNS), as it pertains to a very specific capital event.
2016-05-18 English
Kapitalforhøjelse i Genmab som følge af udnyttelse af medarbejderwarrants
Share Issue/Capital Change Classification · 100% confidence The document is a formal company announcement regarding a capital increase resulting from the exercise of employee warrants. It details the number of shares issued, the subscription prices, and the impact on the company's total share capital. This falls directly under the definition of 'Share Issue/Capital Change' (SHA).
2016-05-18 English
Kapitalforhøjelse i Genmab som følge af udnyttelse af medarbejderwarrants
Share Issue/Capital Change Classification · 100% confidence The document is a corporate announcement from Genmab regarding a capital increase resulting from the exercise of employee warrants. It details the number of shares issued, the subscription prices, and the impact on the company's total share capital. This falls directly under the category of share issuance and capital changes.
2016-05-18 English
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a formal 'Company Announcement' from Genmab A/S dated May 17, 2016. It details a specific regulatory event: the US FDA granting Priority Review to a supplemental Biologics License Application (sBLA) for a drug (ofatumumab). This type of announcement, which communicates a specific regulatory milestone or action (like FDA acceptance, PDUFA date setting, or trial results), is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR) or a transcript (CT), and it specifically announces a regulatory action regarding a drug application, it fits best under the general category for regulatory announcements that aren't explicitly defined elsewhere. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a specific, non-financial regulatory update that doesn't fit the other specialized codes (like DIRS, DIV, CAP, etc.). It is not an Earnings Release (ER) as it focuses purely on regulatory/clinical progress, not period financial results.
2016-05-17 English
Regulatory Filings 2016
Regulatory Filings Classification · 100% confidence The document is explicitly titled 'Company Announcement' and details a specific regulatory event: the US FDA granting Priority Review to a supplemental Biologics License Application (sBLA) for a drug (ofatumumab). It provides key dates (PDUFA target action date of September 10, 2016) and context about clinical trials and the company's pipeline. This is not a full annual report (10-K), an earnings release (ER), or a quarterly report (IR). It is a specific, material announcement concerning regulatory progress and clinical data, which fits best under the general category of Regulatory Filings (RNS) as it is a broad announcement of a regulatory event, or potentially a Legal Proceedings Report (LTR) if the focus was on litigation, but here it is clearly a regulatory update. Given the options, RNS serves as the best general category for non-standard, material regulatory updates that aren't explicitly covered by other codes like DIV or CAP. However, since it is a formal announcement about a regulatory submission and review process, and it is not a standard financial report, RNS is the most appropriate fallback.
2016-05-17 English
Ofatumumab i kombination med fludarabin og cyclofosfamid til behandling af recidiverende CLL tildeles priority-review af de amerikanske sundhedsmyndigheder
Regulatory Filings Classification · 95% confidence The document is a corporate announcement (Selskabsmeddelelse) from Genmab A/S regarding the FDA granting priority review for a supplemental Biologics License Application (sBLA) for the drug ofatumumab. It provides details on the regulatory status, the PDUFA date, and background information on the clinical trial (COMPLEMENT 2). As this is a general regulatory announcement regarding company operations and drug development status that does not fit into specific financial reporting categories like 10-K or IR, it is classified as a Regulatory Filing (RNS).
2016-05-17 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.